BridgeBio Pharma to Participate in November Investor Events
November 09 2022 - 7:30AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that members of the
management team will participate in the following upcoming investor
conferences:
- Jefferies Health Care Conference, London, UK:
November 15th at 9:40 am ET
- Evercore ISI HealthCONx
Conference, Virtual: November 30th at 10:05 am
ET
To access the live webcast of BridgeBio’s presentations, please
visit the “Events” page within the Investors section of the
BridgeBio website at http://investor.bridgebio.com. A replay of the
webcasts will be available on the BridgeBio website for 90 days
following the event.
About BridgeBio Pharma, Inc. BridgeBio
Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical
company founded to discover, create, test and deliver
transformative medicines to treat patients who suffer from genetic
diseases and cancers with clear genetic drivers. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information visit
bridgebio.com and follow us on
LinkedIn and Twitter.
BridgeBio Contact: Vikram
Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024